Drug Trial Radar · NCT01397968
Efficacy and Safety of YKP3089 in Subjects With Treatment Resistant Partial Onset Seizures
Last checked: Nov 19, 2026Latest source record: Apr 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
222
Actual
Start
Jul 6, 2011
Primary completion
Jun 2013
Study completion Jan 28, 2021
Sponsor
- Lead sponsor
- SK Life Science, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 20, 2011
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is to evaluate the efficacy of YKP3089 in reducing seizure frequency when compared to baseline in subjects with partial onset seizures not fully controlled despite their treatment with 1 to 3 concomitant anti-epileptic drugs. Also to evaluate the safety and tolerability of YKP3089.
Conditions
- Partial Epilepsy
Interventions
YKP3089Drug
Capsule, dose to be titrated Tablet, dose to be titrated
PlaceboDrug
Placebo capsule Placebo tablet
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Partial-onset Seizure Frequency Per 28 DaysTime frame: assessed per 28 days during 12 week period; change from baseline and 12 weeks reported
Locations
38 sites in 4 countries. Site status is shown where the registry gives one.
St. Joseph Hospital & Medical Center/Barrow Neurology Clinic
Phoenix, Arizona
Clinical Trials, Inc.
Little Rock, Arkansas
Kaiser Permanente
Anaheim, California
VA Greater Los Angeles Healthcare System
Los Angeles, California
Bradenton Research Center, Inc.
Bradenton, Florida
Bluegrass Epilepsy Research, LLC
Lexington, Kentucky
John's Hopkins University School of Medicine
Baltimore, Maryland
Mid-Atlantic Epilepsy and Sleep Center
Bethesda, Maryland
Suite 209 South
Chesterfield, Missouri
Ohio State University Medical Center
Columbus, Ohio
The University of Toledo
Toledo, Ohio
Lynn Health Science Institute
Oklahoma City, Oklahoma
University of Pennsylvania Health System
Philadelphia, Pennsylvania
Thomas Jefferson University Comprehensive Epilepsy Center
Philadelphia, Pennsylvania
Neurological Clinic of Texas, P.A.
Dallas, Texas
University of Virginia
Charlottesville, Virginia
St. Theresa's General Hospital
Hyderabad, Andhra Pradesh, India
M.S. Ramaiah Medical College and Hospital
Bangalore, Karnataka, India
Bangalore Clinisearch
Bangalore, Karnataka, India
Mallikatta Neuro Centre
Mangalore, Karnataka, India
Deenanath Mangeshkar Hospital & Research Centre
Pune, Maharashtra, India
Max Super Specialty Hospital
Sāket, New Delhi, India
Nightingale Hospital
Kolkata, West Bengal, India
NZOZ Vito-Med Sp. Zo.o
Gliwice, Poland
NZOZ Diagnomed
Katowice, Poland
SPSK Nr 7 SUM w Katowicach, Gornoslaskie CM im. Prof. Leszka Gieca
Katowice, Poland
Malopolskie Centrum Medyczne
Krakow, Poland
Centrum Leczenia Padaczki i Migreny
Krakow, Poland
Centrum Terapii Wspolczesnej
Lodz, Poland
Solumed s.c.
Poznan, Poland
Dong-A University Medical Center
Busan, South Korea
Keimyung University Dongsan Hospital
Daegu, South Korea
Chungnam National University Hospital
Daejeon, South Korea
Hallym University Sacred Heart Hospital
Gyeonggi-do, South Korea
Seoul National University Hospital
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Korea University Anam Hospital
Seoul, South Korea
Asan Medical Center
Seoul, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.